Yuji Komizu Selected Research

Dimyristoylphosphatidylcholine (DMPC)

1/2016	Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.
6/2013	Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells.
2/2012	Hybrid liposomes inhibit growth and invasion of human osteosarcoma cells leading to apoptosis.
2/2012	Selective accumulation and growth inhibition of hybrid liposomes to human hepatocellular carcinoma cells in relation to fluidity of plasma membranes.
7/2011	Selective accumulation of hybrid liposomes into adult T-cell leukemia cells along with induction of apoptosis.
1/2011	Remarkable inhibitory effects of hybrid liposomes on growth of human colon cancer cells through induction of cell cycle arrest along with apoptosis.
1/2011	[Experimental therapeutic effects of hybrid liposomes on the Alzheimer's disease in vitro].
1/2011	Therapeutic effects of hybrid liposomes composed of phosphatidylcholine and docosahexaenoic acid on the hepatic metastasis of colon carcinoma along with apoptosis in vivo.
6/2010	Hybrid liposomes inhibit the growth of cholangiocarcinoma by induction of cell cycle arrest in G1 phase.
12/2006	Membrane targeted chemotherapy with hybrid liposomes for colon tumor cells leading to apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuji Komizu Research Topics

Disease

11	Neoplasms (Cancer) 01/2016 - 12/2006
5	Neoplasm Metastasis (Metastasis) 11/2019 - 01/2011
3	Lung Neoplasms (Lung Cancer) 11/2019 - 01/2016
3	Infections 02/2015 - 03/2010
2	Osteosarcoma (Osteogenic Sarcoma) 06/2013 - 02/2012
2	Hepatocellular Carcinoma (Hepatoma) 07/2012 - 02/2012
2	Carcinoma (Carcinomatosis) 01/2011 - 10/2008
2	Primary Effusion Lymphoma 07/2010 - 03/2010
1	Carcinogenesis 08/2021
1	Liver Neoplasms (Liver Cancer) 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016
1	Wounds and Injuries (Trauma) 02/2012
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 07/2011
1	Colonic Neoplasms (Colon Cancer) 01/2011
1	Alzheimer Disease (Alzheimer's Disease) 01/2011
1	Neuroblastoma 01/2011
1	Cholangiocarcinoma 06/2010

Drug/Important Bio-Agent (IBA)

18	Liposomes (Liposome)IBA 01/2019 - 12/2006
10	Dimyristoylphosphatidylcholine (DMPC)IBA 01/2016 - 12/2006
8	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 06/2013 - 12/2006
5	Ether (Diethyl Ether)IBA 06/2013 - 12/2006
3	dihydroceramide desaturaseIBA 11/2019 - 01/2016
3	Therapeutic UsesIBA 06/2013 - 01/2011
3	LipidsIBA 02/2012 - 01/2011
3	EthersIBA 02/2012 - 01/2011
2	Caspase 3 (Caspase-3)IBA 02/2012 - 07/2011
1	Epithelial Cell Adhesion MoleculeIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	RV 538 (PDMP)IBA 01/2016
1	CeramidesIBA 01/2016
1	SphingolipidsIBA 01/2016
1	ceramide glucosyltransferaseIBA 01/2016
1	GUT-70IBA 02/2015
1	cepharanthineIBA 05/2014
1	CaspasesIBA 07/2012
1	matrigelIBA 02/2012
1	Docosahexaenoic AcidsIBA 01/2011
1	Unithiol (DMPS)IBA 01/2011
1	Amyloid (Amyloid Fibrils)IBA 01/2011
1	Ammonium CompoundsIBA 01/2011
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2011
1	Peptides (Polypeptides)IBA 01/2011
1	PropaneIBA 01/2011
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2011
1	dimyristoylphosphatidylserineIBA 01/2011

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 06/2013 - 12/2006
1	Cell Transplantation 08/2021
1	Therapeutics 01/2019
1	Intravenous Injections 01/2011